Breaking News

Sunday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/25/20
10/25
04:55
10/25/20
04:55
AKBA

Akebia

$3.18 /

-0.065 (-2.01%)

, ALNY

Alnylam

$131.62 /

-2.7 (-2.01%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.06 /

-0.84 (-0.37%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

, BAX

Baxter

$81.08 /

-0.35 (-0.43%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$26.00 /

-1.16 (-4.27%)

, ICUI

ICU Medical

$192.47 /

-2.01 (-1.03%)

, TCDA

Tricida

$8.74 /

-0.17 (-1.91%)

, SNY

Sanofi

$49.33 /

+0.39 (+0.80%)

, GSK

GlaxoSmithKline

$35.30 /

+0.22 (+0.63%)

, FOLD

Amicus

$18.48 /

+0.455 (+2.52%)

, FMS

Fresenius Medical

$40.87 /

+0.75 (+1.87%)

, DRNA

Dicerna

$19.38 /

-0.32 (-1.62%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$58.92 /

+3.93 (+7.15%)

, KDNY

Chinook Therapeutics

$15.34 /

-0.1 (-0.65%)

, RTRX

Retrophin

$20.91 /

-0.12 (-0.57%)

, OMER

Omeros

$10.66 /

-0.4 (-3.62%)

, OM

Outset Medical

$50.00 /

+1.8 (+3.73%)

, NVS

Novartis

$84.41 /

-0.04 (-0.05%)

, VRTX

Vertex Pharmaceuticals

$211.52 /

+1.34 (+0.64%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.06 /

-0.84 (-0.37%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
BAX Baxter
$81.08 /

-0.35 (-0.43%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.74 /

-0.17 (-1.91%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.48 /

+0.455 (+2.52%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$10.66 /

-0.4 (-3.62%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$50.00 /

+1.8 (+3.73%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.41 /

-0.04 (-0.05%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

OM Outset Medical
$50.00 /

+1.8 (+3.73%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

Saturday
Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/24/20
10/24
04:55
10/24/20
04:55
AKBA

Akebia

$3.18 /

-0.065 (-2.01%)

, ALNY

Alnylam

$131.62 /

-2.7 (-2.01%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.06 /

-0.84 (-0.37%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

, BAX

Baxter

$81.08 /

-0.35 (-0.43%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$26.00 /

-1.16 (-4.27%)

, ICUI

ICU Medical

$192.47 /

-2.01 (-1.03%)

, TCDA

Tricida

$8.74 /

-0.17 (-1.91%)

, SNY

Sanofi

$49.33 /

+0.39 (+0.80%)

, GSK

GlaxoSmithKline

$35.30 /

+0.22 (+0.63%)

, FOLD

Amicus

$18.48 /

+0.455 (+2.52%)

, FMS

Fresenius Medical

$40.87 /

+0.75 (+1.87%)

, DRNA

Dicerna

$19.38 /

-0.32 (-1.62%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$58.92 /

+3.93 (+7.15%)

, KDNY

Chinook Therapeutics

$15.34 /

-0.1 (-0.65%)

, RTRX

Retrophin

$20.91 /

-0.12 (-0.57%)

, OMER

Omeros

$10.66 /

-0.4 (-3.62%)

, OM

Outset Medical

$50.00 /

+1.8 (+3.73%)

, NVS

Novartis

$84.41 /

-0.04 (-0.05%)

, VRTX

Vertex Pharmaceuticals

$211.52 /

+1.34 (+0.64%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

10/23/20 Piper Sandler
Akebia rally justified as vadadustat has chance, says Piper Sandler
10/23/20 JPMorgan
JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval
09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.06 /

-0.84 (-0.37%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
BAX Baxter
$81.08 /

-0.35 (-0.43%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.74 /

-0.17 (-1.91%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.48 /

+0.455 (+2.52%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.87 /

+0.75 (+1.87%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$10.66 /

-0.4 (-3.62%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$50.00 /

+1.8 (+3.73%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.41 /

-0.04 (-0.05%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

RTRX Retrophin
$20.91 /

-0.12 (-0.57%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

ICUI ICU Medical
$192.47 /

-2.01 (-1.03%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

DRNA Dicerna
$19.38 /

-0.32 (-1.62%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.33 /

+0.39 (+0.80%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

FOLD Amicus
$18.48 /

+0.455 (+2.52%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

TCDA Tricida
$8.74 /

-0.17 (-1.91%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

OMER Omeros
$10.66 /

-0.4 (-3.62%)

OM Outset Medical
$50.00 /

+1.8 (+3.73%)

NVS Novartis
$84.41 /

-0.04 (-0.05%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

CCXI ChemoCentryx
$58.92 /

+3.93 (+7.15%)

CALT Calliditas Therapeutics
$26.00 /

-1.16 (-4.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.08 /

-0.35 (-0.43%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

ALNY Alnylam
$131.62 /

-2.7 (-2.01%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

VRTX Vertex Pharmaceuticals
$211.52 /

+1.34 (+0.64%)

SNY Sanofi
$49.33 /

+0.39 (+0.80%)

KDNY Chinook Therapeutics
$15.34 /

-0.1 (-0.65%)

GSK GlaxoSmithKline
$35.30 /

+0.22 (+0.63%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AMGN Amgen
$227.06 /

-0.84 (-0.37%)

AKBA Akebia
$3.18 /

-0.065 (-2.01%)

Over a week ago
Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/23/20
10/23
04:55
10/23/20
04:55
AKBA

Akebia

$3.24 /

-0.055 (-1.67%)

, ALNY

Alnylam

$134.33 /

-2.12 (-1.55%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$227.87 /

-0.99 (-0.43%)

, AZN

AstraZeneca

$51.98 /

+0.42 (+0.81%)

, BAX

Baxter

$81.44 /

-0.43 (-0.53%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$27.18 /

+0.18 (+0.67%)

, ICUI

ICU Medical

$194.10 /

+1.73 (+0.90%)

, TCDA

Tricida

$8.91 /

+0.1 (+1.14%)

, SNY

Sanofi

$48.91 /

-0.3 (-0.61%)

, GSK

GlaxoSmithKline

$35.08 /

-0.28 (-0.79%)

, FOLD

Amicus

$18.02 /

+0.36 (+2.04%)

, FMS

Fresenius Medical

$40.13 /

+0.33 (+0.83%)

, DRNA

Dicerna

$19.70 /

+0.63 (+3.30%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$54.99 /

+2.88 (+5.53%)

, KDNY

Chinook Therapeutics

$15.48 /

-0.25 (-1.59%)

, RTRX

Retrophin

$21.03 /

+0.23 (+1.11%)

, OMER

Omeros

$11.06 /

-0.11 (-0.98%)

, OM

Outset Medical

$48.91 /

+3.36 (+7.38%)

, NVS

Novartis

$84.45 /

+0.32 (+0.38%)

, VRTX

Vertex Pharmaceuticals

$210.18 /

-1.25 (-0.59%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$210.18 /

-1.25 (-0.59%)

TCDA Tricida
$8.91 /

+0.1 (+1.14%)

SNY Sanofi
$48.91 /

-0.3 (-0.61%)

RTRX Retrophin
$21.03 /

+0.23 (+1.11%)

OMER Omeros
$11.06 /

-0.11 (-0.98%)

NVS Novartis
$84.45 /

+0.32 (+0.38%)

KDNY Chinook Therapeutics
$15.48 /

-0.25 (-1.59%)

ICUI ICU Medical
$194.10 /

+1.73 (+0.90%)

GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

FOLD Amicus
$18.02 /

+0.36 (+2.04%)

FMS Fresenius Medical
$40.13 /

+0.33 (+0.83%)

DRNA Dicerna
$19.70 /

+0.63 (+3.30%)

CCXI ChemoCentryx
$54.99 /

+2.88 (+5.53%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.44 /

-0.43 (-0.53%)

AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

AMGN Amgen
$227.87 /

-0.99 (-0.43%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$134.33 /

-2.12 (-1.55%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
09/04/20 Mizuho
Akebia price target lowered to $6 from $17 at Mizuho
ALNY Alnylam
$134.33 /

-2.12 (-1.55%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$227.87 /

-0.99 (-0.43%)

10/22/20 Oppenheimer
Amgen price target lowered to $275 from $280 at Oppenheimer
10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
BAX Baxter
$81.44 /

-0.43 (-0.53%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$27.18 /

+0.18 (+0.67%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$194.10 /

+1.73 (+0.90%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.91 /

+0.1 (+1.14%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$48.91 /

-0.3 (-0.61%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$18.02 /

+0.36 (+2.04%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$40.13 /

+0.33 (+0.83%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.70 /

+0.63 (+3.30%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$54.99 /

+2.88 (+5.53%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.48 /

-0.25 (-1.59%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$21.03 /

+0.23 (+1.11%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$11.06 /

-0.11 (-0.98%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$48.91 /

+3.36 (+7.38%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.45 /

+0.32 (+0.38%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$210.18 /

-1.25 (-0.59%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$210.18 /

-1.25 (-0.59%)

TCDA Tricida
$8.91 /

+0.1 (+1.14%)

SNY Sanofi
$48.91 /

-0.3 (-0.61%)

RTRX Retrophin
$21.03 /

+0.23 (+1.11%)

OMER Omeros
$11.06 /

-0.11 (-0.98%)

NVS Novartis
$84.45 /

+0.32 (+0.38%)

ICUI ICU Medical
$194.10 /

+1.73 (+0.90%)

GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

FOLD Amicus
$18.02 /

+0.36 (+2.04%)

DRNA Dicerna
$19.70 /

+0.63 (+3.30%)

CCXI ChemoCentryx
$54.99 /

+2.88 (+5.53%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.44 /

-0.43 (-0.53%)

AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

AMGN Amgen
$227.87 /

-0.99 (-0.43%)

ALNY Alnylam
$134.33 /

-2.12 (-1.55%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$48.91 /

-0.3 (-0.61%)

NVS Novartis
$84.45 /

+0.32 (+0.38%)

GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

FOLD Amicus
$18.02 /

+0.36 (+2.04%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

AMGN Amgen
$227.87 /

-0.99 (-0.43%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

VRTX Vertex Pharmaceuticals
$210.18 /

-1.25 (-0.59%)

TCDA Tricida
$8.91 /

+0.1 (+1.14%)

SNY Sanofi
$48.91 /

-0.3 (-0.61%)

OMER Omeros
$11.06 /

-0.11 (-0.98%)

OM Outset Medical
$48.91 /

+3.36 (+7.38%)

NVS Novartis
$84.45 /

+0.32 (+0.38%)

GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

CCXI ChemoCentryx
$54.99 /

+2.88 (+5.53%)

CALT Calliditas Therapeutics
$27.18 /

+0.18 (+0.67%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.44 /

-0.43 (-0.53%)

AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

AMGN Amgen
$227.87 /

-0.99 (-0.43%)

ALNY Alnylam
$134.33 /

-2.12 (-1.55%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

VRTX Vertex Pharmaceuticals
$210.18 /

-1.25 (-0.59%)

SNY Sanofi
$48.91 /

-0.3 (-0.61%)

KDNY Chinook Therapeutics
$15.48 /

-0.25 (-1.59%)

GSK GlaxoSmithKline
$35.08 /

-0.28 (-0.79%)

AZN AstraZeneca
$51.98 /

+0.42 (+0.81%)

AMGN Amgen
$227.87 /

-0.99 (-0.43%)

AKBA Akebia
$3.24 /

-0.055 (-1.67%)

Hot Stocks
Retrophin to acquire Orphan Technologies for $90M upfront » 16:09
10/22/20
10/22
16:09
10/22/20
16:09
RTRX

Retrophin

$21.05 /

+0.25 (+1.20%)

Retrophin announced that…

Retrophin announced that it has entered into a definitive agreement to acquire Orphan Technologies, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria, or HCU. OT-58 is a novel investigational enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical HCU, a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications, as well as developmental delay. OT-58 is a PEGylated, recombinant enzyme replacement therapy designed to address the underlying cause of classical HCU - a deficiency in the naturally occurring enzyme cystathionine beta synthase, or CBS. A deficiency in CBS prevents regular metabolism from occurring and results in elevated levels of homocysteine. In preclinical studies, OT-58 has demonstrated an ability to reduce total homocysteine levels and improve clinical parameters. Specifically, dosing of OT-58 in mouse models corrected metabolite levels, including up to 90% reduction in homocysteine levels in plasma and tissues, and appeared to prolong survival, prevent osteoporosis and rescue ocular structure. OT-58 is currently advancing in a Phase 1/2 dose escalation study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. OT-58 has been granted Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Drug designation in the U.S. and Europe. Under the terms of the agreement, Retrophin will make an upfront payment of $90M in cash upon closing of the transaction. Orphan Technologies shareholders will also be eligible to receive up to $427M in additional cash payments contingent upon the achievement of key milestones in the development and commercialization of OT-58. Retrophin will also pay a tiered mid-single digit royalty on future net sales of OT-58 in the U.S. and Europe, and potentially make a milestone payment in the event a pediatric rare disease voucher is granted. The transaction has been approved by the boards of directors of both companies. It is subject to customary closing conditions, including consummation of a spinout agreement for Orphan Technologies' preclinical OT-15 product candidate, and is anticipated to close in Q4.

ShowHide Related Items >><<
RTRX Retrophin
$21.05 /

+0.25 (+1.20%)

RTRX Retrophin
$21.05 /

+0.25 (+1.20%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
RTRX Retrophin
$21.05 /

+0.25 (+1.20%)

  • 09
    Jun
Conference/Events
Chinook Therapeutics to host conference call » 15:55
10/22/20
10/22
15:55
10/22/20
15:55
KDNY

Chinook Therapeutics

$15.36 /

-0.37 (-2.35%)

Conference call to…

Conference call to discuss abstracts as presented at ASN Kidney Week 2020, will be held on October 22 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$15.36 /

-0.37 (-2.35%)

KDNY Chinook Therapeutics
$15.36 /

-0.37 (-2.35%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
KDNY Chinook Therapeutics
$15.36 /

-0.37 (-2.35%)

Hot Stocks
Alnylam: Lumasiran showed 72% reduction in urinary oxalate in Phase 3 study » 10:06
10/22/20
10/22
10:06
10/22/20
10:06
ALNY

Alnylam

$139.87 /

+3.42 (+2.51%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals announced results from the 6-month primary analysis of the ILLUMINATE-B Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 - the gene encoding glycolate oxidase - in development for the treatment of adults and children with primary hyperoxaluria type 1. Results were presented from ILLUMINATE-B, as well as new 12-month results from the ILLUMINATE-A pivotal Phase 3 study and the ongoing Phase 2 open-label extension study, at the American Society of Nephrology Kidney Week 2020 held as a virtual event on October 22-25. Lumasiran is under review by the FDA and received a Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on October 16, 2020. If approved, lumasiran will be marketed as OXLUMO. The efficacy results and safety profile of lumasiran were found to be similar to those observed in adults and children 6 years or older in the ILLUMINATE-A study. Treatment with lumasiran in ILLUMINATE-B led to a 72 percent mean reduction in spot urinary oxalate:creatinine ratio from baseline to Month 6, averaged across months 3 to 6 - the primary endpoint of the study. Lumasiran also demonstrated positive results across secondary endpoints, including proportion of patients achieving urinary oxalate levels at or below 1.5 times ULNa. Preliminary analysis of exploratory endpoints indicated improvements in nephrocalcinosis in 8 out of 18 patients, while estimated glomerular filtration rates remained stable. At baseline, 14 of 18 patients had nephrocalcinosis. After 6 months of lumasiran treatment, no patients worsened, 10 remained stable, and eight showed bilateral or unilateral improvements in nephrocalcinosis. As expected, given the 6-month duration of the study, there was no change in the rate of renal stone events.

ShowHide Related Items >><<
ALNY Alnylam
$139.87 /

+3.42 (+2.51%)

ALNY Alnylam
$139.87 /

+3.42 (+2.51%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALNY Alnylam
$139.87 /

+3.42 (+2.51%)

ALNY Alnylam
$139.87 /

+3.42 (+2.51%)

Conference/Events
Chinook Therapeutics to host conference call » 04:55
10/22/20
10/22
04:55
10/22/20
04:55
KDNY

Chinook Therapeutics

$15.73 /

-1 (-5.98%)

Conference call to…

Conference call to discuss abstracts as presented at ASN Kidney Week 2020, will be held on October 22 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/22/20
10/22
04:55
10/22/20
04:55
AKBA

Akebia

$3.30 /

-0.265 (-7.44%)

, ALNY

Alnylam

$136.52 /

-4.93 (-3.49%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$228.86 /

-2.28 (-0.99%)

, AZN

AstraZeneca

$51.56 /

-0.62 (-1.19%)

, BAX

Baxter

$81.87 /

+0.62 (+0.76%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$27.00 /

-0.57 (-2.07%)

, ICUI

ICU Medical

$192.37 /

+0.44 (+0.23%)

, TCDA

Tricida

$8.81 /

-0.01 (-0.11%)

, SNY

Sanofi

$49.19 /

-0.77 (-1.54%)

, GSK

GlaxoSmithKline

$35.36 /

-0.68 (-1.89%)

, FOLD

Amicus

$17.66 /

+0.69 (+4.07%)

, FMS

Fresenius Medical

$39.80 /

+0.01 (+0.03%)

, DRNA

Dicerna

$19.07 /

-0.12 (-0.63%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$51.99 /

-1.45 (-2.71%)

, KDNY

Chinook Therapeutics

$15.73 /

-1 (-5.98%)

, RTRX

Retrophin

$20.68 /

-0.21 (-1.01%)

, OMER

Omeros

$11.14 /

-0.12 (-1.07%)

, OM

Outset Medical

$45.59 /

-0.79 (-1.70%)

, NVS

Novartis

$84.15 /

-1.6 (-1.87%)

, VRTX

Vertex Pharmaceuticals

$211.36 /

-3.24 (-1.51%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$211.36 /

-3.24 (-1.51%)

TCDA Tricida
$8.81 /

-0.01 (-0.11%)

SNY Sanofi
$49.19 /

-0.77 (-1.54%)

RTRX Retrophin
$20.68 /

-0.21 (-1.01%)

OMER Omeros
$11.14 /

-0.12 (-1.07%)

NVS Novartis
$84.15 /

-1.6 (-1.87%)

KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

ICUI ICU Medical
$192.37 /

+0.44 (+0.23%)

GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

FOLD Amicus
$17.66 /

+0.69 (+4.07%)

FMS Fresenius Medical
$39.80 /

+0.01 (+0.03%)

DRNA Dicerna
$19.07 /

-0.12 (-0.63%)

CCXI ChemoCentryx
$51.99 /

-1.45 (-2.71%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.87 /

+0.62 (+0.76%)

AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

AMGN Amgen
$228.86 /

-2.28 (-0.99%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$136.52 /

-4.93 (-3.49%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
09/04/20 Mizuho
Akebia price target lowered to $6 from $17 at Mizuho
ALNY Alnylam
$136.52 /

-4.93 (-3.49%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$228.86 /

-2.28 (-0.99%)

10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
BAX Baxter
$81.87 /

+0.62 (+0.76%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/21/20 Morgan Stanley
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley
10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$27.00 /

-0.57 (-2.07%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$192.37 /

+0.44 (+0.23%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.81 /

-0.01 (-0.11%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.19 /

-0.77 (-1.54%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$17.66 /

+0.69 (+4.07%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$39.80 /

+0.01 (+0.03%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.07 /

-0.12 (-0.63%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$51.99 /

-1.45 (-2.71%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.68 /

-0.21 (-1.01%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$11.14 /

-0.12 (-1.07%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$45.59 /

-0.79 (-1.70%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$84.15 /

-1.6 (-1.87%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$211.36 /

-3.24 (-1.51%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$211.36 /

-3.24 (-1.51%)

TCDA Tricida
$8.81 /

-0.01 (-0.11%)

SNY Sanofi
$49.19 /

-0.77 (-1.54%)

RTRX Retrophin
$20.68 /

-0.21 (-1.01%)

OMER Omeros
$11.14 /

-0.12 (-1.07%)

NVS Novartis
$84.15 /

-1.6 (-1.87%)

ICUI ICU Medical
$192.37 /

+0.44 (+0.23%)

GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

FOLD Amicus
$17.66 /

+0.69 (+4.07%)

DRNA Dicerna
$19.07 /

-0.12 (-0.63%)

CCXI ChemoCentryx
$51.99 /

-1.45 (-2.71%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.87 /

+0.62 (+0.76%)

AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

AMGN Amgen
$228.86 /

-2.28 (-0.99%)

ALNY Alnylam
$136.52 /

-4.93 (-3.49%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.19 /

-0.77 (-1.54%)

NVS Novartis
$84.15 /

-1.6 (-1.87%)

GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

FOLD Amicus
$17.66 /

+0.69 (+4.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

AMGN Amgen
$228.86 /

-2.28 (-0.99%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

VRTX Vertex Pharmaceuticals
$211.36 /

-3.24 (-1.51%)

TCDA Tricida
$8.81 /

-0.01 (-0.11%)

SNY Sanofi
$49.19 /

-0.77 (-1.54%)

OMER Omeros
$11.14 /

-0.12 (-1.07%)

OM Outset Medical
$45.59 /

-0.79 (-1.70%)

NVS Novartis
$84.15 /

-1.6 (-1.87%)

GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

CCXI ChemoCentryx
$51.99 /

-1.45 (-2.71%)

CALT Calliditas Therapeutics
$27.00 /

-0.57 (-2.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.87 /

+0.62 (+0.76%)

AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

AMGN Amgen
$228.86 /

-2.28 (-0.99%)

ALNY Alnylam
$136.52 /

-4.93 (-3.49%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

VRTX Vertex Pharmaceuticals
$211.36 /

-3.24 (-1.51%)

SNY Sanofi
$49.19 /

-0.77 (-1.54%)

KDNY Chinook Therapeutics
$15.73 /

-1 (-5.98%)

GSK GlaxoSmithKline
$35.36 /

-0.68 (-1.89%)

AZN AstraZeneca
$51.56 /

-0.62 (-1.19%)

AMGN Amgen
$228.86 /

-2.28 (-0.99%)

AKBA Akebia
$3.30 /

-0.265 (-7.44%)

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/21/20
10/21
04:55
10/21/20
04:55
AKBA

Akebia

$3.56 /

-0.14 (-3.78%)

, ALNY

Alnylam

$141.42 /

+0.82 (+0.58%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$231.14 /

+0.29 (+0.13%)

, AZN

AstraZeneca

$52.18 /

-0.26 (-0.50%)

, BAX

Baxter

$81.25 /

+0.05 (+0.06%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$27.57 /

-0.14 (-0.51%)

, ICUI

ICU Medical

$190.81 /

-0.26 (-0.14%)

, TCDA

Tricida

$8.82 /

-0.185 (-2.05%)

, SNY

Sanofi

$49.96 /

-0.21 (-0.42%)

, GSK

GlaxoSmithKline

$36.04 /

-0.14 (-0.39%)

, FOLD

Amicus

$16.97 /

+0.12 (+0.71%)

, FMS

Fresenius Medical

$39.85 /

-1.62 (-3.91%)

, DRNA

Dicerna

$19.17 /

-0.88 (-4.39%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$53.44 /

-0.19 (-0.35%)

, KDNY

Chinook Therapeutics

$16.73 /

+0.57 (+3.53%)

, RTRX

Retrophin

$20.89 /

-0.45 (-2.11%)

, OMER

Omeros

$11.26 /

+0.2 (+1.81%)

, OM

Outset Medical

$46.38 /

-1.85 (-3.84%)

, NVS

Novartis

$85.75 /

-0.02 (-0.02%)

, VRTX

Vertex Pharmaceuticals

$214.65 /

-6.06 (-2.75%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$214.65 /

-6.06 (-2.75%)

TCDA Tricida
$8.82 /

-0.185 (-2.05%)

SNY Sanofi
$49.96 /

-0.21 (-0.42%)

RTRX Retrophin
$20.89 /

-0.45 (-2.11%)

OMER Omeros
$11.26 /

+0.2 (+1.81%)

NVS Novartis
$85.75 /

-0.02 (-0.02%)

KDNY Chinook Therapeutics
$16.73 /

+0.57 (+3.53%)

ICUI ICU Medical
$190.81 /

-0.26 (-0.14%)

GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

FOLD Amicus
$16.97 /

+0.12 (+0.71%)

FMS Fresenius Medical
$39.85 /

-1.62 (-3.91%)

DRNA Dicerna
$19.17 /

-0.88 (-4.39%)

CCXI ChemoCentryx
$53.44 /

-0.19 (-0.35%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.25 /

+0.05 (+0.06%)

AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

AMGN Amgen
$231.14 /

+0.29 (+0.13%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$141.42 /

+0.82 (+0.58%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
09/04/20 Mizuho
Akebia price target lowered to $6 from $17 at Mizuho
ALNY Alnylam
$141.42 /

+0.82 (+0.58%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$231.14 /

+0.29 (+0.13%)

10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
BAX Baxter
$81.25 /

+0.05 (+0.06%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
10/02/20 Deutsche Bank
Bayer price target lowered to EUR 64 from EUR 82 at Deutsche Bank
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$27.57 /

-0.14 (-0.51%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$190.81 /

-0.26 (-0.14%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$8.82 /

-0.185 (-2.05%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$49.96 /

-0.21 (-0.42%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$16.97 /

+0.12 (+0.71%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$39.85 /

-1.62 (-3.91%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$19.17 /

-0.88 (-4.39%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$53.44 /

-0.19 (-0.35%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$16.73 /

+0.57 (+3.53%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$20.89 /

-0.45 (-2.11%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$11.26 /

+0.2 (+1.81%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OM Outset Medical
$46.38 /

-1.85 (-3.84%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$85.75 /

-0.02 (-0.02%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$214.65 /

-6.06 (-2.75%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$214.65 /

-6.06 (-2.75%)

TCDA Tricida
$8.82 /

-0.185 (-2.05%)

SNY Sanofi
$49.96 /

-0.21 (-0.42%)

RTRX Retrophin
$20.89 /

-0.45 (-2.11%)

OMER Omeros
$11.26 /

+0.2 (+1.81%)

NVS Novartis
$85.75 /

-0.02 (-0.02%)

ICUI ICU Medical
$190.81 /

-0.26 (-0.14%)

GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

FOLD Amicus
$16.97 /

+0.12 (+0.71%)

DRNA Dicerna
$19.17 /

-0.88 (-4.39%)

CCXI ChemoCentryx
$53.44 /

-0.19 (-0.35%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.25 /

+0.05 (+0.06%)

AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

AMGN Amgen
$231.14 /

+0.29 (+0.13%)

ALNY Alnylam
$141.42 /

+0.82 (+0.58%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$49.96 /

-0.21 (-0.42%)

NVS Novartis
$85.75 /

-0.02 (-0.02%)

GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

FOLD Amicus
$16.97 /

+0.12 (+0.71%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

AMGN Amgen
$231.14 /

+0.29 (+0.13%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

VRTX Vertex Pharmaceuticals
$214.65 /

-6.06 (-2.75%)

TCDA Tricida
$8.82 /

-0.185 (-2.05%)

SNY Sanofi
$49.96 /

-0.21 (-0.42%)

OMER Omeros
$11.26 /

+0.2 (+1.81%)

OM Outset Medical
$46.38 /

-1.85 (-3.84%)

NVS Novartis
$85.75 /

-0.02 (-0.02%)

GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

CCXI ChemoCentryx
$53.44 /

-0.19 (-0.35%)

CALT Calliditas Therapeutics
$27.57 /

-0.14 (-0.51%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.25 /

+0.05 (+0.06%)

AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

AMGN Amgen
$231.14 /

+0.29 (+0.13%)

ALNY Alnylam
$141.42 /

+0.82 (+0.58%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

VRTX Vertex Pharmaceuticals
$214.65 /

-6.06 (-2.75%)

SNY Sanofi
$49.96 /

-0.21 (-0.42%)

KDNY Chinook Therapeutics
$16.73 /

+0.57 (+3.53%)

GSK GlaxoSmithKline
$36.04 /

-0.14 (-0.39%)

AZN AstraZeneca
$52.18 /

-0.26 (-0.50%)

AMGN Amgen
$231.14 /

+0.29 (+0.13%)

AKBA Akebia
$3.56 /

-0.14 (-3.78%)

Conference/Events
Chinook Therapeutics to host conference call » 11:45
10/20/20
10/20
11:45
10/20/20
11:45
KDNY

Chinook Therapeutics

$17.50 /

+1.34 (+8.29%)

Conference call to…

Conference call to discuss abstracts as presented at ASN Kidney Week 2020, will be held on October 22 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$17.50 /

+1.34 (+8.29%)

KDNY Chinook Therapeutics
$17.50 /

+1.34 (+8.29%)

10/20/20 Oppenheimer
Chinook Therapeutics upgraded to Outperform from Perform at Oppenheimer
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
KDNY Chinook Therapeutics
$17.50 /

+1.34 (+8.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.